A primary obligation of medical journals is the responsible, professional and expeditious delivery of knowledge from researchers and practitioners to the wider community \[[@gfaa153-B1]\]. The task of journal editors, therefore, rests not merely in selecting what to publish, but in large measure judging how it can best be communicated. The challenge of improving descriptions of kidney function and disease in medical publishing was the impetus for a Kidney Disease: Improving Global Outcomes (KDIGO) Consensus Conference held in June 2019. The conference goals included standardizing and refining kidney-related nomenclature used in English-language scientific articles and developing a glossary that can be used by journals \[[@gfaa153-B2]\].

The rationale for the conference was that the worldwide burden of kidney disease is rising, but public awareness remains limited, underscoring the need for effective communication by stakeholders in the kidney health community \[[@gfaa153-B3]\]. Despite this need, the nomenclature for describing kidney function and disease lacks uniformity and clarity. Two decades ago, a survey of hundreds of published articles and meeting abstracts reported a broad array of overlapping, confusing terms for chronic kidney disease (CKD) and advocated adoption of unambiguous terminology \[[@gfaa153-B7]\]. Nevertheless, terms flagged by that analysis as problematic, such as 'chronic renal failure' (CRF) and 'pre-dialysis', still appear in current-day publications. A coherent, shared nomenclature could improve communication at all levels, to not only foster better appreciation of the burden of disease but also aid understanding of how patients feel about their disease, allow more effective communication between kidney disease specialists and other clinicians, advance more straightforward comparison and integration of datasets, enable better recognition of gaps in knowledge for future research and facilitate more comprehensive public health policies for acute and chronic kidney disease.

Developing consistent, patient-centered and precise descriptions of kidney function and disease in the scientific literature is an important objective to align communication in clinical practice, research and public health. Although some terms have been in use for decades, the increased exchange of information among stakeholders makes it timely to revisit nomenclature in order to ensure consistency. The goal is to facilitate communication within and across disciplines and between practitioners and patients, with the ultimate hope of improving outcomes through consistency and precision.

Attendees at the conference included editors of kidney subspecialty journals, kidney subspecialty editors at general medical journals and journals from other subspecialties, experienced authors of clinical kidney health research and patients. The guiding principles of the conference were that the revised nomenclature should be patient-centered, precise and consistent with nomenclature used in the KDIGO guidelines. The discussion focused on general description of acute and CKD and kidney measures, rather than specific kidney diseases and particular measures of function and structure. Classifications of causes of kidney disease and procedures, performance measures and outcome metrics for dialysis and transplantation were considered beyond the scope of discussion.

As described in detail in the conference report \[[@gfaa153-B8]\], the meeting attendees reached general consensus on the following recommendations: (i) to use 'kidney' rather than 'renal' or 'nephro-' when referring to kidney disease and kidney function; (ii) to use 'kidney failure' with appropriate descriptions of presence or absence of symptoms, signs and treatment rather than 'end-stage kidney disease' (ESKD); (iii) to use the KDIGO definition and classification of acute kidney diseases and disorders and acute kidney injury (AKI) rather than alternative descriptions to define and classify the severity of these; (iv) to use the KDIGO definition and classification of CKD rather than alternative descriptions to define and classify it; and (v) to use specific kidney measures, such as albuminuria or decreased glomerular filtration rate (GFR), rather than 'abnormal' or 'reduced' kidney function to describe alterations in kidney structure and function ([Table 1](#gfaa153-T1){ref-type="table"}). Accordingly, the proposed glossary contains five corresponding sections, and comprises specific items for which there was general agreement among the conference participants (<https://kdigo.org/conferences/nomenclature/>; [Table 2](#gfaa153-T2){ref-type="table"}) \[[@gfaa153-B8]\]. For each section, the glossary includes preferred terms, abbreviations, descriptions and terms to avoid, with the acknowledgment that journals may choose which of the recommendations to implement, and that journal style will dictate when and how to abbreviate terms to be consistent with nomenclature for other diseases.

###### 

Key takeaways from the conference

  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Use the term 'kidney' rather than 'renal' to describe kidney function and kidney disease. In English, the terms renal and kidney are still used interchangeably, resulting in different acronyms describing the same condition or status (e.g. ESRD/ESKD and RRT/KRT). It is more likely that patients and the public would understand the terms incorporating the more familiar noun 'kidney', rather than the less familiar adjective 'renal', which is derived from Latin and is labeled as technical in some dictionaries. Although writing guides may generally favor using an appropriate adjective over a noun as a modifier, there are high-profile precedents for the use of kidney as a modifier, such as AKI, CKD and NIDDK.
  Avoid the term 'end-stage'. Although rooted in US law, the term is not patient sensitive, may connote a stigma and may discourage advocacy. In the USA, ESRD (ESKD) is a synonym for receipt of KRT. However, KRT is a treatment rather than a disease. The term 'kidney failure', which is defined as GFR \<15 mL/min/1.73 m^2^ or treatment by dialysis, is as comprehensive as 'ESRD/ESKD', without suffering from its limitations.
  Improve characterization of the full spectrum of kidney failure. Although all patients with kidney failure have GFR \<15 mL/min/1.73 m^2^ or are undergoing treatment by dialysis, the severity of symptoms varies greatly. We lack terms to describe the severity of symptoms and signs, and yet they are indications for initiating KRT. There are also no common patient-reported outcome measures to describe severity. The term 'kidney failure' in a chronic setting is defined as \>3 months, whereas in an acute setting (i.e. AKI Stage 3), it is reserved for a duration of ≤3 months. Kidney failure could be further classified according to patient-reported outcomes (symptoms).
  Use more-descriptive terms for treatments for kidney failure. Many patients with kidney failure do not undergo KRT. The terms 'treated' versus 'untreated' have been used, but this is not consistent with the idea that supportive care is indeed treatment. Furthermore, in some cases, patients choose supportive care rather than KRT; in other cases, they do not have a choice because of lack of insurance or lack of availability. Finally, some patients may not be under the care of a physician at all.
  Avoid the use of 'chronic kidney disease (CKD)' as a synonym for 'GFR \<60 mL/min/1.73 m^2^'. CKD includes markers of kidney damage or GFR \<60 mL/min/1.73 m^2^ for \>3 months, so ascertainment of GFR without assessment for markers of kidney damage is insufficient for classification of CKD status when GFR is \>60 mL/min/1.73 m^2^. If chronicity is not documented, it can be inferred on the basis of corroborative clinical data or presumed in the absence of clinical data to the contrary.
  Avoid the use of 'acute kidney injury (AKI)' as a synonym for AKD'. AKD refers to kidney diseases and disorders with a duration of ≤3 months, whereas AKI refers to kidney diseases and disorders with onset within 1 week.
  Use 'CKD GFR and albuminuria categories' and 'AKI stages' to describe disease severity, rather than employing ill-defined terms such as 'mild', 'moderate', 'severe' and 'advanced'.
  Use the terms 'GFR categories' and 'albuminuria categories' rather than 'CKD stages' when describing the level of GFR and albuminuria in populations either without CKD or without ascertainment of both GFR and albuminuria.
  Use the term 'risk categories' to describe combinations of the G (GFR) and A (albuminuria) categories from the KDIGO heat map (see [Supplementary data](#sup1){ref-type="supplementary-material"}, [Figure S1](#sup1){ref-type="supplementary-material"}).
  Use specific terms, such as 'GFR', 'tubular secretion', 'tubular reabsorption', 'albuminuria' and 'proteinuria', rather than general terms, such as 'abnormal' or 'reduced' kidney function, damage or injury, when possible. Because kidney function comprises several functional categories, including excretory, endocrine and metabolic functions, it should be described as specifically as possible. GFR is closely linked with the excretory function, but it should not be used as a synonym, because TR and excretion also contribute to excretory function.
  When referring to 'decreased or decreasing GFR', avoid the use of different, poorly defined terms such as 'impaired kidney function', 'renal insufficiency', 'renal dysfunction', 'renal impairment', 'worsening kidney function' and 'kidney function decline'.
  When referring to GFR, use descriptive abbreviations mGFR for measured GFR and eGFR for estimated GFR, with specific notation based on the endogenous filtration markers used (e.g. eGFR~cr~, eGFR~cys~ and eGFR~cr-cys~). Additional detail can be given in the methods. For mGFR, the methods should describe the exogenous filtration marker (e.g. inulin, iothalamate and iohexol) and clearance method (urinary clearance and plasma clearance). For eGFR, the methods should describe the estimating equation used (CKD-EPI; MDRD Study).
  Avoid referring to 'albuminuria' or 'proteinuria' as 'decreased kidney function'. Albuminuria and proteinuria are markers of kidney damage, rather than measures of kidney function.
  When referring to albuminuria or proteinuria, avoid the terms 'microalbuminuria' and 'macroalbuminuria/clinical proteinuria'. Use the terms 'moderately increased' or 'severely increased' instead.
  When referring to albuminuria and proteinuria, use descriptive abbreviations, such as 'urine albumin or protein excretion rates (AER and PER)' and 'urine albumin--creatinine or protein--creatinine ratios (ACR and PCR)'.
  -----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ACR, albumin--creatinine ratio; AER, albumin excretion rate; AKD, acute kidney diseases and disorders; AKI, acute kidney injury; CKD, chronic kidney disease; CKD-EPI, CKD Epidemiology Collaboration; eGFR, estimated GFR; eGFR~cr~, estimated GFR derived from creatinine; eGFR~cr-cys~, estimated GFR derived from creatinine and cystatin C; eGFR~cys~, estimated GFR derived from cystatin C; ESKD, end-stage kidney disease; ESRD, end-stage renal disease; GFR, glomerular filtrationrate; KDIGO, Kidney Disease: Improving Global Outcomes; KRT, kidney replacement therapy; MDRD, Modification of Diet in Renal Disease; mGFR, measured GFR; NIDDK, National Institute of Diabetes and Digestive and Kidney Diseases; PCR, protein--creatinine ratio; PER, protein excretion rate; RRT, renal replacement therapy; US, United States.

###### 

KDIGO kidney function and disease glossary: suggested terms to describe kidney function and kidney disease, and criteria and measures defining them

  Preferred term                                                                             Suggested abbreviations[^a^](#tblfn3){ref-type="table-fn"}  Rationale/explanation                                                                                                                                                                                                                                                                                                                                                                                                             Terms to avoid
  ----------------------------------------------------------------------------------------- ------------------------------------------------------------ --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  **Part 1**. **Kidney function and disease**                                                                                                            The term 'kidney' should be used preferentially when describing kidney disease and kidney function, with exceptions                                                                                                                                                                                                                                                                                                               'Renal', the prefix 'nephro-' (except in the setting of specific functions, diseases, or syndromes; see below)
  **Kidney disease**                                                                                                                                     Reflects the entirety of AKD and CKD                                                                                                                                                                                                                                                                                                                                                                                              Renal disease, nephropathy (except in the setting of specific diseases, e.g. membranous nephropathy)
  **Kidney function**                                                                                                                                    Reflects the entirety of different and complex physiological functions of the kidney; should not be equated with GFR only                                                                                                                                                                                                                                                                                                         Renal function (except when describing specific functions, e.g. renal acidification, renal concentrating mechanism)
   Normal kidney function                                                                                                                                General term applicable to various aspects of kidney function that should be specified                                                                                                                                                                                                                                                                                                                                            
   Abnormal kidney function                                                                                                                              General term applicable to various aspects of kidney function that should be specified                                                                                                                                                                                                                                                                                                                                            Renal/kidney impairment, insufficiency, dysfunction, azotemia
   Residual kidney function                                                                                             RKF                              Kidney function in people with kidney failure receiving KRT; further specification is required, e.g. urine flow rate, solute clearance. Although it is usually used in the setting of dialysis, this term could be used to refer to native kidney function in kidney transplant recipients                                                                                                                                        Residual renal function (RRF)
  **Kidney structure**                                                                                                                                   Reflects the entirety of different and complex structures of the kidney, ascertained by imaging and markers of injury and damage                                                                                                                                                                                                                                                                                                  Renal structure (except when describing specific structures within the kidney, such as artery, vein, capsule, parenchyma, cortex, medulla, glomeruli, tubules, interstitium, cysts, tumors)
   Normal kidney structure                                                                                                                               General term applicable to various aspects of kidney structure that should be specified                                                                                                                                                                                                                                                                                                                                           
   Abnormal kidney structure                                                                                                                             General term applicable to various aspects of kidney structure that should be specified                                                                                                                                                                                                                                                                                                                                           
  **Causes of kidney disease**                                                                                                                           Cause of AKI, AKD, and CKD should be indicated whenever possible. Cause may be known, presumed, or unknown. Method for ascertainment and attribution of cause should be specified                                                                                                                                                                                                                                                 Cause should not be inferred only from presence of comorbid condition (such as diabetes)
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Part 2**. **Kidney failure**                                                                                                                         GFR \<15 mL/min/1.73 m^2^ or treatment by dialysis; further specification is required; see below                                                                                                                                                                                                                                                                                                                                  RF; ESRD; ESKD; renal disease; nephropathy; renal/kidney impairment, insufficiency, dysfunction; azotemia
  **Duration**                                                                                                                                           Specification preferred                                                                                                                                                                                                                                                                                                                                                                                                           
   Acute kidney injury Stage 3[^b^](#tblfn4){ref-type="table-fn"}                                                   AKI Stage 3                          Disease duration ≤3 months                                                                                                                                                                                                                                                                                                                                                                                                        Acute RF; renal disease; nephropathy; renal/kidney impairment, insufficiency, dysfunction; azotemia; uremia
   Kidney failure                                                                                                        KF                              Disease duration \>3  months                                                                                                                                                                                                                                                                                                                                                                                                      CRF; chronic renal disease; chronic nephropathy; chronic renal/kidney impairment, insufficiency, dysfunction; azotemia; uremia; irreversible kidney failure
  **Symptoms and signs**                                                                                                                                 Specification preferred (with, without, or unknown symptoms and signs); with symptoms and signs would be synonymous with uremia                                                                                                                                                                                                                                                                                                   
   Uremia/uremic syndrome                                                                                                                                A syndrome consisting of symptoms and signs associated with kidney failure (does not indicate a causal role for urea)                                                                                                                                                                                                                                                                                                             
  **Treatment**                                                                                                                                          Specification required                                                                                                                                                                                                                                                                                                                                                                                                            
   Kidney replacement therapy[^c^](#tblfn5){ref-type="table-fn"}                                                        KRT                              Further specification is required; includes dialysis and transplantation                                                                                                                                                                                                                                                                                                                                                          RRT
    Dialysis                                                                                                        AKI Stage 3D                         AKI Stage 3 treated by dialysis                                                                                                                                                                                                                                                                                                                                                                                                   AKI-D; dialysis-dependent AKI
                                                                                                                      CKD G5D                            CKD G5 treated by dialysis                                                                                                                                                                                                                                                                                                                                                                                                        ESKD; ESKF; ESRD; ESRF; dialysis-dependent CKD
     Duration                                                                                                                                            Long-term versus short-term: long-term refers to dialysis for CKD, and may also be referred to as maintenance dialysis; short-term refers to dialysis for AKD                                                                                                                                                                                                                                                                     Chronic dialysis, acute dialysis (the terms acute and chronic refer to duration of kidney disease rather than duration of dialysis treatment)
     Modality and frequency                                                                                                                              ModalitiesHD; HF; HDF; PD, ambulatory or automatedFrequencycontinuous; intermittent (short or prolonged)                                                                                                                                                                                                                                                                                                                          
    Kidney transplantation                                                                                          CKD G1T--G5T                         CKD G1--G5 after transplantation                                                                                                                                                                                                                                                                                                                                                                                                  ESKD; ESKF; ESRD; ESRF
     Donor source                                                                                                                                        Specify LDKT or DDKT                                                                                                                                                                                                                                                                                                                                                                                                              
   Kidney failure with replacement therapy                                                                              KFRT                             CKD G5 treated by dialysis or CKD G1--G5 after transplantation; for epidemiologic studies, both should be included                                                                                                                                                                                                                                                                                                                ESKD; ESKF; ESRD; ESRF
   Kidney failure without replacement therapy                                                                    CKD G5 without KRT                      Further specification is preferred: specify whether KRT is not chosen versus not available                                                                                                                                                                                                                                                                                                                                        ESKD; ESKF; ESRD; ESRF; untreated kidney failure
    With comprehensive conservative care                                                                                                                 Further specification is preferred; definition is evolving                                                                                                                                                                                                                                                                                                                                                                        
    Without comprehensive conservative care                                                                                                              Further specification is preferred: specify whether comprehensive conservative care is not chosen versus not available                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Part 3**. **Acute kidney diseases and disorders (AKD) and acute kidney injury (AKI)**                                                                Disease duration ≤3 months; conceptually different from initial recognition of CKD                                                                                                                                                                                                                                                                                                                                                ARF; ARI
  **Acute kidney diseases**                                                                            AKD[^c^](#tblfn5){ref-type="table-fn"}            KDIGO definition: AKI, or GFR \<60  mL/min/1.73 m^2^, or markers of kidney damage for ≤3 months, or decrease in GFR by ≥35% or increase in SCr by \>50% for ≤3 months                                                                                                                                                                                                                                                             ARF; ARI
  **Acute kidney injury**                                                                                               AKI                              KDIGO definition (AKI is a subcategory of AKD): oliguria for \>6 h, rise in SCr by \>0.3  mg/dL in 2 days or by \>50% in 1  week                                                                                                                                                                                                                                                                                                  ARF; ARI
  **AKI classification**                                                                                                                                 KDIGO classification by cause and stage preferred rather than stage alone; e.g. a patient with AKI Stage 3 due to ATN; classification applies to all AKI stages                                                                                                                                                                                                                                                                   Previous classifications, including RIFLE and AKIN (the KDIGO classification harmonized these prior definitions)
  **AKI stages**                                                                                                                                         KDIGO definition (applicable only to people with AKI)                                                                                                                                                                                                                                                                                                                                                                             
                                                                                                                    AKI Stage 1                          SCr and/or urine output criteria                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                    AKI Stage 2                          SCr and/or urine output criteria                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                    AKI Stage 3                          SCr and/or urine output criteria                                                                                                                                                                                                                                                                                                                                                                                                  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Part 4**. **CKD**                                                                                                                                    Disease duration \>3 months                                                                                                                                                                                                                                                                                                                                                                                                       CRF; ESRD; renal/kidney impairment, insufficiency, dysfunction
  **CKD**                                                                                                                                                KDIGO definition: GFR \<60 mL/min/1.73 m^2^ or markers of kidney damage for \>3 months                                                                                                                                                                                                                                                                                                                                            CRF; ESRD; renal/kidney impairment, insufficiency, dysfunction
  **CKD classification**                                                                                                                                 KDIGO CGA classification by cause, GFR category (G1--G5), and albuminuria category (A1--A3); see below for definitions of G and A categories. For example, a patient with CKD G1, A3 due to diabetes or a cohort with CKD G4--G5, A1--A3 of any cause. Note that CKD classification is only applicable to people with CKD, so a patient could not be classified as 'CKD G2, A1' if there was no other evidence of kidney damage   Mild, moderate, severe, early, advanced CKD; CKD Stages 1--5 (complete description preferred rather than G category alone)
    CKD without KRT                                                                                               CKD without KRT                        CKD G1--G5, A1--A3 of any cause, not receiving dialysis or transplantation                                                                                                                                                                                                                                                                                                                                                        ND-CKD; NDD-CKD; predialysis CKD; pre-ESRD CKD
  **CKD risk categories**                                                                                                                                KDIGO definitions (colors refer to heat map in [Supplementary Figure S1](#sup1){ref-type="supplementary-material"}) unless otherwise defined; risk depends on the outcome being considered                                                                                                                                                                                                                                        Mild, moderate, severe, early, advanced CKD
    CKD risk category---low                                                                                           Low risk                           Refers to G1A1, G2A1 (green)                                                                                                                                                                                                                                                                                                                                                                                                      
    CKD risk category---moderately high                                                                            Moderate risk                         Refers to G1A2, G2A2, G3aA1 (yellow)                                                                                                                                                                                                                                                                                                                                                                                              
   CKD risk category---high                                                                                          High risk                           Refers to G1A3, G2A3, G3aA2, G3bA1 (orange)                                                                                                                                                                                                                                                                                                                                                                                       
   CKD risk category---very high                                                                                   Very high risk                        Refers to G3aA3, G3bA2, G3bA3, G4A1, G4A2, G4A3, G5A1, G5A2, G5A3 (red)                                                                                                                                                                                                                                                                                                                                                           
  **CKD progression**                                                                                                                                    Refers to worsening GFR or albuminuria. Other biomarkers not included. There is not yet consensus on use of specific terms to describe the timing (e.g. early, late) or rate (fast, slow) of progression. Use of specific terms should be defined in methods.Further specification may be required: GFR decline may occur during therapy for other conditions, which may not be considered as CKD progression                     
  **CKD remission**                                                                                                                                      Refers to improving GFR or albuminuria. Criteria depend on disease. Use of specific terms should be defined in methods                                                                                                                                                                                                                                                                                                            
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  **Part 5**. **Kidney measures**                                                                                                                        Applies to people with or without kidney disease; consider measurement issues (methods) and variability (multiple measures may improve classification)                                                                                                                                                                                                                                                                            
  **Glomerular filtration rate and clearance**                                                                                                           GFR and creatinine clearance are not synonymous                                                                                                                                                                                                                                                                                                                                                                                   
   Glomerular filtration rate                                                                                           GFR                              Units must be specified (mL/min/1.73 m^2^ or mL/min)                                                                                                                                                                                                                                                                                                                                                                              
    Measured glomerular filtration rate                                                                                 mGFR                             Clearance methods and exogenous filtration markers should be noted separately in methods                                                                                                                                                                                                                                                                                                                                          
    Estimated glomerular filtration rate                                                                                eGFR                             Estimating equations (e.g. CKD-EPI and MDRD Study) and filtration markers (e.g. creatinine and cystatin C) should be noted separately in methods                                                                                                                                                                                                                                                                                  
    Estimated glomerular filtration rate; marker                                                                      eGFR~cr~                           eGFR using creatinine                                                                                                                                                                                                                                                                                                                                                                                                             
  eGFR~cys~                                                                                                    eGFR using cystatin C                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  eGFR~cr-cys~                                                                                          eGFR using creatinine and cystatin C                                                                                                                                                                                                                                                                                                                                                                                                                                               
   Clearance                                                                                                             Cl                              Solute must be specified; units must be specified (mL/min/1.73 m^2^ or mL/min)                                                                                                                                                                                                                                                                                                                                                    
    Measured clearance                                                                                                  mCl                              Clearance methods and markers should be noted separately in methods                                                                                                                                                                                                                                                                                                                                                               
    Measured clearance; marker                                                                                        mCl~UN~                            mCl using urea nitrogen                                                                                                                                                                                                                                                                                                                                                                                                           
  mCl~cr~                                                                                                       mCl using creatinine                                                                                                                                                                                                                                                                                                                                                                                                                                                       
  mCl~UN-cr~                                                                                           mCl using urea nitrogen and creatinine                                                                                                                                                                                                                                                                                                                                                                                                                                              
    Estimated clearance                                                                                                 eCl                              Estimating equations (e.g. Cockcroft--Gault) and markers should be noted separately in methods                                                                                                                                                                                                                                                                                                                                    
    Estimated clearance; marker                                                                                       eCl~cr~                            eCl using creatinine                                                                                                                                                                                                                                                                                                                                                                                                              
  **GFR categories**                                                                                                                                     For use in describing GFR level irrespective of the presence or absence of kidney disease; GFR units are mL/min/1.73 m^2^ for these categories; multiple categories can be collapsed (e.g. G3--G5)                                                                                                                                                                                                                                
   Normal to increased GFR                                                                                               G1                              GFR ≥90 mL/min/1.73 m^2^                                                                                                                                                                                                                                                                                                                                                                                                          
   Mildly reduced GFR                                                                                                    G2                              GFR 60--89 mL/min/1.73 m^2^                                                                                                                                                                                                                                                                                                                                                                                                       
   Moderately reduced GFR                                                                                               G3a                              GFR 45--59  mL/min/1.73 m^2^                                                                                                                                                                                                                                                                                                                                                                                                      
  G3b                                                                                                       GFR 30--44 mL/min/1.73 m^2^                                                                                                                                                                                                                                                                                                                                                                                                                                                    
   Severely reduced GFR                                                                                                  G4                              GFR 15--29 mL/min/ 1.73 m^2^                                                                                                                                                                                                                                                                                                                                                                                                      
   Kidney failure                                                                                                        G5                              GFR \<15 mL/min/ 1.73 m^2^ or treated by dialysis                                                                                                                                                                                                                                                                                                                                                                                 
   Hyperfiltration                                                                                                                                       The concept of hyperfiltration is generally accepted but not consistently defined. If this term is used as an exposure, outcome, or covariate, the GFR threshold must be defined (e.g. \>120 mL/min/ 1.73 m^2^)                                                                                                                                                                                                                   Renal hyperfiltration
   GFR reserve                                                                                                                                           The concept of GFR reserve is generally accepted as the difference between stimulated and basal GFR                                                                                                                                                                                                                                                                                                                               Renal function reserve
  **Albuminuria and proteinuria**                                                                                                                        Specify measurement conditions (spot versus timed samples; quantitative versus dipstick); differentiate nonalbumin proteins as clinically indicated                                                                                                                                                                                                                                                                               
  **Albuminuria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Microalbuminuria; macroalbuminuria
   Urinary albumin concentration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Urinary albumin excretion rate                                                                                       AER                              Requires timed urine collection; interval for urine collection should be noted separately in methods; unit of time may vary (hour or day)                                                                                                                                                                                                                                                                                         
   Urinary albumin-- creatinine ratio                                                                                   ACR                              From timed urine collection or spot urine collection; interval for timed urine collection, or time of day for spot urine collection, should be noted separately in methods                                                                                                                                                                                                                                                        
  **Proteinuria**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          Clinical proteinuria; overt proteinuria
   Urinary protein concentration                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
   Urinary protein excretion rate                                                                                       PER                              Requires timed urine collection; interval for urine collection should be noted separately in methods; unit of time may vary (hour or day)                                                                                                                                                                                                                                                                                         
   Urinary protein--creatinine ratio                                                                                    PCR                              From timed urine collection or spot urine collection; interval for timed urine collection, or time of day for spot urine collection, should be noted separately in methods                                                                                                                                                                                                                                                        
  **Albuminuria and proteinuria categories**                                                                                                             For use in describing albuminuria or proteinuria level irrespective of the presence or absence of kidney disease                                                                                                                                                                                                                                                                                                                  
   Normal                                                                                                                                                AER \<10  mg/day; ACR \<10 mg/g (\<1 mg/mmol)                                                                                                                                                                                                                                                                                                                                                                                     Normoalbuminuria
   Mildly increased (mild)                                                                                                                               AER 10--29 mg/day; ACR 10--29 mg/g (1.0--2.9 mg/mmol)                                                                                                                                                                                                                                                                                                                                                                             
   Normal to mildly increased (normal to mild)                                                                           A1                              AER \<30 mg/day; ACR \<30  mg/g (\<3  mg/mmol); PER \<150  mg/day; PCR \<150  mg/g (\<15 mg/mmol)                                                                                                                                                                                                                                                                                                                                 
   Moderately increased (moderate)                                                                                       A2                              AER 30--300 mg/day; ACR 30--300 mg/g (3--30 mg/mmol); PER 150--500 mg/day; PCR 150--500 mg/g (15--50 mg/mmol)                                                                                                                                                                                                                                                                                                                     Microalbuminuria
   Severely increased (severe)                                                                                           A3                              AER  \>300  mg/day; ACR \>300 mg/g (\>30 mg/mmol); PER \>500 mg/day; PCR \>500 mg/g (\>50 mg/mmol)                                                                                                                                                                                                                                                                                                                                Macroalbuminuria; clinical proteinuria; overt proteinuria
   Nephrotic-range/syndrome[^d^](#tblfn6){ref-type="table-fn"}                                                                                           AER \>2200 mg/day; ACR \>2200 mg/g (\>220 mg/mmol);PER \>3500 mg/day; PCR \>3500 mg/g (\>350 mg/mmol)Specify with or without nephrotic syndrome, as noted by the presence of hypoalbuminemia (with edema and hyperlipidemia in most cases)                                                                                                                                                                                        
  **Tubular function**                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     
   Tubular secretion                                                                                                     TS                              Further specification is required to distinguish rate, clearance, or fraction (compared with filtered load)                                                                                                                                                                                                                                                                                                                       
   Tubular reabsorption                                                                                                  TR                              Further specification is required to distinguish rate, clearance, or fraction (compared with filtered load)                                                                                                                                                                                                                                                                                                                       
   Fractional excretion, marker                                                                                        FE~Na~                            FE of sodium                                                                                                                                                                                                                                                                                                                                                                                                                      
   Fractional reabsorption, marker                                                                                     FR~Na~                            FR of sodium                                                                                                                                                                                                                                                                                                                                                                                                                      

ACR, albumin-creatinine ratio; AER, albumin excretion rate; AKD, acute kidney diseases and disorders; AKI, acute kidney injury; AKIN, Acute Kidney Injury Network; ARF, acute renal failure; ARI, acute renal insufficiency; ATN, acute tubular necrosis; CGA, cause, GFR category and albuminuria category; CKD, chronic kidney disease; CKD-EPI, CKD Epidemiology Collaboration; CRF, chronic renal failure; DDKT, deceased donor kidney transplant/transplantation; eGFR, estimated glomerular filtration rate; ESKD, end-stage kidney disease; ESKF, end-stage kidney failure; ESRD, end-stage renal disease; ESRF, end-stage renal failure; FE~Na~, fractional excretion, sodium; FR~Na~, fractional reabsorption, sodium; GFR, glomerular filtration rate; HD, hemodialysis; HDF, hemodiafiltration; HF, hemofiltration; KDIGO, Kidney Disease: Improving Global Outcomes; KFRT, kidney failure with replacement therapy; KRT, kidney replacement therapy; LDKT, living donor kidney transplant/transplantation; MDRD, Modification of Diet in Renal Disease; mGFR, measured GFR; ND-CKD, nondialysis CKD; NDD-CKD, nondialysis-dependent CKD; PCR, protein-creatinine ratio; PD, peritoneal dialysis; PER, protein excretion rate; pre-ESRD, pre--end-stage renal disease; RF, renal failure; RIFLE, Risk, Injury, Failure, Loss of kidney function, and end-stage kidney disease; RRT, renal replacement therapy; SCr, serum creatinine; TR, tubular reabsorption; TS, tubular secretion.

Journal style will dictate whether and when to abbreviate terms.

Ongoing discussion; may be revised by KDIGO AKI guideline update.

Ongoing discussion; may be revised by KDIGO AKD consensus conference.

Ongoing discussion; may be revised by KDIGO Glomerulonephritis guideline update.

A guiding principle for the development of the glossary was patient-centeredness. The Health and Medicine Division of the US National Academies of Sciences defines patient-centered care as '\[p\]roviding care that is respectful of, and responsive to, individual patient preferences, needs and values, and ensuring that patient values guide all clinical decisions' \[[@gfaa153-B9]\]. One of the 10 general principles recommended for redesign of the health system is: 'Knowledge is shared and information flows freely. Patients should have unfettered access to their own medical information and to clinical knowledge. Clinicians and patients should communicate effectively and share information'. In principle, the terms used to describe kidney function and disease should be understandable to all, with acknowledgment of variation in the level of health literacy. Use of multiple terms with similar meaning can lead to confusion, as can use of terms that forecast the future (such as 'pre-dialysis') rather than describe the present. However, convergence of multiple names into an accepted set of terms does require that users of the glossary are willing to accept that labels that have been preeminent historically, and that may be more familiar or memorable even now, should now be superseded \[[@gfaa153-B10]\].

Of equal importance to patient-centeredness in the development of the glossary was precision, which can generally be defined as exactness or accuracy \[[@gfaa153-B10]\]. How medicine is defined and understood is changing rapidly from a descriptive, disease-based categorization in which multiple pathogenetic pathways may be conflated to a mechanism-based categorization that will promote more precise management of clinical problems. The latter approach, in which a molecular profile is added to the clinical and morphologic profile, has already revolutionized diagnosis and treatment in oncology. In Nephrology, the ongoing Kidney Precision Medicine Project, funded by the National Institutes of Health, seeks to ethically obtain and evaluate kidney biopsies from participants with AKI or CKD; create a kidney tissue atlas; define disease subgroups; and identify cells, pathways and targets for novel therapies \[[@gfaa153-B11]\]. As has occurred in oncology, it is anticipated that refinements that result in more precise disease descriptions will be incorporated into current nomenclature for kidney function and disease, rather than replace it altogether. Thus, although the glossary is designed to be consistent with current knowledge and stable enough to remain relevant for the foreseeable future, it is also intended to be sufficiently flexible to accommodate new vocabulary arising with advances in the field.

A central strength of the proposed glossary is that it is based on existing KDIGO definitions, classifications and nomenclature for acute and chronic kidney disease. In addition, it was developed using the following: a systematic process, including articulation of a clear and transparent rationale (patient-centeredness and precision); capture of stakeholder viewpoints via patient focus groups \[[@gfaa153-B12]\] and a corresponding survey; a period of public comment on conference scope; and attainment of consensus among attendees at the conference. Although the recommendations are not likely to answer all concerns, the consensus among conference attendees was that standardizing scientific nomenclature is a necessary first step to improving communications among clinicians, researchers and public health officials, and with patients, their families and caregivers and the public.

Limitations of the proposed glossary are that it is restricted to English (nuances may be difficult to translate); only a limited number of stakeholders were able to participate, owing to practical reasons; it is not comprehensive (it does not include disease classification, dialysis, transplantation); and further specification is required for studies in children. For these and other reasons, we consider the current recommendations for a glossary to be an important starting point, and it will require future expansion and updating.

Achieving consensus among conference attendees, and publication of the conference report and glossary, is only the first step in implementation of a revised nomenclature. The glossary will be freely available on the KDIGO website (<https://kdigo.org/conferences/nomenclature/>; [Table 2](#gfaa153-T2){ref-type="table"}). Elements of the glossary will be included in online updates to the newly released (11th) edition of the *AMA Manual of Style* \[[@gfaa153-B13]\]. Medical journals adopting the recommendations will need to determine how to implement them, and this process will require education of editorial staff as well as proactive communication with authors, generally and with regard to specific manuscripts. If successful, then further implementation in clinical practice, research and public health will require more widespread dissemination and professional education. Improving communication with patients and the public will require efforts to improve patient education and health literacy for the public, and guides to communication with patients. Professional societies, industry and patient advocacy organizations will be critical to these efforts.

Advances in research, particularly in precision medicine, will introduce a myriad of new terms and novel concepts requiring incorporation into disease definitions and classifications. In addition, the increasing prominence and participation of patient and caregiver communities in defining research and best practices in clinical care will further elucidate the characteristics of patient-centered terminology. Expanding and updating the KDIGO glossary can be accomplished as part of the activities of future KDIGO guideline workgroups and conferences.

Supplementary Material
======================

###### 

Click here for additional data file.

This article is being published in *Kidney International Reports* and reprinted concurrently in several journals. The articles cover identical concepts and wording but vary in minor stylistic and spelling changes, detail and length of manuscript, in keeping with each journal's style. Any of these versions may be used in citing this article. Excerpts are adapted with permission of KDIGO and the International Society of Nephrology.
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